Oncology Pharma (ONPH) Ratios
Oncology Pharma Ratios
ONPH's free cash flow for Q3 2022 was $-1.98K. For the 2022 fiscal year, ONPH's free cash flow was increased by $0.00 and operating cash flow was $-1.98K. See a summary of the company’s cash flow.
| Ratios | Mar 22 | Mar 21 | Mar 20 | Mar 19 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 0.00 | 0.02 | 0.01 | 0.02 |
| Quick Ratio | 0.00 | 0.02 | 0.01 | 0.02 |
| Cash Ratio | 0.00 | 0.02 | 0.01 | 0.02 |
| Solvency Ratio | -119.24 | -188.33 | -0.70 | -2.11 |
| Operating Cash Flow Ratio | 0.42 | -0.23 | -0.08 | -0.09 |
| Short-Term Operating Cash Flow Coverage | 0.56 | -0.49 | -0.17 | -0.16 |
| Net Current Asset Value | $ -871.51K | $ -508.61K | $ -292.71K | $ -396.45K |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.31 | 0.69 | 0.56 | 1.25 |
| Debt-to-Equity Ratio | 0.53 | -1.40 | -2.03 | -1.12 |
| Debt-to-Capital Ratio | 0.35 | 3.49 | 1.97 | 9.36 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.70 | -2.04 | -3.63 | -0.90 |
| Debt Service Coverage Ratio | 0.00 | -0.18 | -1.18 | -3.03 |
| Interest Coverage Ratio | -0.00 | -0.17 | -16.16 | -25.97 |
| Debt to Market Cap | 0.01 | 0.00 | 0.04 | 0.08 |
| Interest Debt Per Share | 3.45 | 5.76 | 0.09 | 0.23 |
| Net Debt to EBITDA | 2.88 | -0.02 | -0.70 | -0.28 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 168616.81% | 676.34% | 51.39% | 103.85% |
| Return on Assets (ROA) | -4929.26% | -28045.46% | -89.91% | -446.31% |
| Return on Equity (ROE) | -8389.65% | 57333.09% | 326.02% | 399.96% |
| Return on Capital Employed (ROCE) | -4.98% | 8476.74% | 634.39% | 385.13% |
| Return on Invested Capital (ROIC) | -3.25% | -21077.60% | -614.30% | -3219.80% |
| Return on Tangible Assets | -4929.26% | -28045.46% | -89.91% | -446.31% |
| Earnings Yield | -92.56% | -32.81% | -6.17% | -28.24% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | 0.01 | -0.01 | -0.01 | -0.03 |
| Free Cash Flow Per Share | 0.01 | -0.01 | -0.01 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -29269.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -29269.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.56 | -0.49 | -0.17 | -0.16 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | 0.33% | -0.04% | -0.67% | -1.23% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -1.08 | -3.05 | -16.19 | -3.54 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 90.64 | -1747.22 | -52.80 | -14.17 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 306.66 | -2537.23 | -149.96 | -81.60 |
| Price-to-Operating Cash Flow Ratio | 306.66 | -2537.23 | -149.96 | -81.60 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.00 | 0.19 | 0.00 |
| Enterprise Value Multiple | 497.19 | -20.28 | -19.23 | -3.97 |
| Enterprise Value | 113.70M | 297.28M | 3.49M | 3.24M |
| EV to EBITDA | 497.19 | -20.28 | -19.23 | -3.97 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 308.45 | -2539.19 | -155.66 | -87.87 |
| EV to Operating Cash Flow | 308.45 | -2539.19 | -155.66 | -87.87 |
| Tangible Book Value Per Share | 0.04 | -0.01 | -0.04 | -0.18 |
| Shareholders’ Equity Per Share | 0.04 | -0.01 | -0.04 | -0.18 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.42 | -6.76 | -0.12 | -0.72 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 13279.19 | 6.65 | 1.14 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.00 | 0.00 | 0.11 | 0.04 |
Currency in USD
